CLINUVEL PHARMACEUTICALS LIMITED - Announcements

0.16%

$12.22

Market Cap $612.5M

Healthcare Biotechnology

Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on... Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.More

ASX:AFP

Could this ASX stock become the next Pfizer? A look at AFT Pharmaceuticals (ASX:AFP). With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for stocks in the sector with room to run. Latest:...

Announcements

Filter Results

All Price Sensitive Only

CUV	Positive preliminary results in Singaporean vitiligo study	PRICE SENSITIVE	03/12/15	133.07KB	Share
CUV	Results of Meeting		24/11/15	102KB	Share
CUV	CEO's AGM Presentation		24/11/15	2.98MB	Share
CUV	Chairman's Address to Shareholders		24/11/15	102.79KB	Share
CUV	Change in substantial holding		04/11/15	3.33MB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/15	137.79KB	Share
CUV	Appendix 4G and Corporate Governance Statement		23/10/15	679.3KB	Share
CUV	Annual Report to shareholders		23/10/15	3.46MB	Share
CUV	Notice of Annual General Meeting/Proxy Form		23/10/15	651.05KB	Share
CUV	Change in substantial holding		07/10/15	559.76KB	Share
CUV	AGM Date		06/10/15	254.13KB	Share
CUV	FDA Meeting		05/10/15	268.27KB	Share
CUV	Becoming a substantial holder		23/09/15	773.09KB	Share
CUV	SCENESSE released for European Distribution	PRICE SENSITIVE	21/09/15	284.3KB	Share
CUV	Preliminary Final Report	PRICE SENSITIVE	31/08/15	1.03MB	Share
CUV	FDA grants Clinuvel a Type C Meeting	PRICE SENSITIVE	27/08/15	143.62KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/15	138.06KB	Share
CUV	Ceasing to be a substantial holder		30/07/15	159.82KB	Share
CUV	Clinuvel Newsletter - July 2015		15/07/15	175.38KB	Share
CUV	NEJM publishes Phase III SCENESSE studies	PRICE SENSITIVE	02/07/15	134.46KB	Share
CUV	SCENESSE Commercialisation Update	PRICE SENSITIVE	05/06/15	282.58KB	Share
CUV	Clinuvel announces innovative melanocortin	PRICE SENSITIVE	05/05/15	131.32KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	27/04/15	137.52KB	Share
CUV	Clinuvel Relocates Melbourne Office		31/03/15	205.87KB	Share
CUV	Appendix 3B		20/03/15	547.71KB	Share
CUV	SCENESSE data presented at US dermatology conference		20/03/15	119.32KB	Share
CUV	SCENESSE breakthrough featured in peer-reviewed editorial		20/03/15	115.97KB	Share
CUV	Clinuvel Newsletter - March 2015		12/03/15	1.09MB	Share
MPL +3PL AAC AAX ABY TSN ACO ACX AFA AFJ AGO AMI ANG APO ASH ASZ ATR AVG AWN AXZ AZZ BAL BCI BDR BGG BLA BLX BRL BYI CGW PRG COF AEL CPL CTD CTP CUV CVN CYG MCM DSH E88 EAX EHE EHL ELD K2P EML ENN FAR FML FPH TOY FWD GBG GBT GEG GFY ETM GMF GNE GNG GOR GOW GDA HCH HFR HGO HSN HUO HZN A1M ILU IMD IPD IPH IQE ISN IWG JIN LAU VBC LHC LOV LYC LYL FDM MDL MFG MGX MIG MIN MND MXI NAN NHF NTU NWF NWT WFL OCL OML PAN ATH PEN PGR PHI PME POS PSQ HYD REG RFF RHP RSG RUL SDA SDL SEK SFX SHJ SHV SIO SIQ SLX SOM SRF SYR TGA TIG TOF TRY TZN UBN VET VLW WLF WOR ZSP	S&P DJ Indices Announces March Quarterly Review	PRICE SENSITIVE	06/03/15	100.19KB	Share
CUV	Appendix 3B		02/03/15	550KB	Share
CUV	Half Yearly Report and Accounts	PRICE SENSITIVE	25/02/15	265.55KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/15	138.2KB	Share
CUV	Change of Director's Interest Notice		23/01/15	728.77KB	Share
CUV	Appendix 3B		23/01/15	549.52KB	Share
CUV	Initial Director's Interest Notice		21/01/15	342.33KB	Share
CUV	Clinuvel appoints new Non-Executive Director		21/01/15	210.85KB	Share
CUV	European Commission approves SCENESSE	PRICE SENSITIVE	23/12/14	275.65KB	Share
CUV	Change of Director's Interest Notice x 3		23/12/14	681.88KB	Share
CUV	Appendix 3B		23/12/14	544.6KB	Share
CUV	Long term use of SCENESSE in EPP published in BJD		15/12/14	121.02KB	Share
CUV	Change in substantial holding		05/12/14	278.54KB	Share
CUV	*Change of Director's Interest Notice 4**		04/12/14	857.15KB	Share
CUV	Appendix 3B		04/12/14	548.6KB	Share
CUV	Investor Update Presentation		04/12/14	1.13MB	Share
CUV	Results of Meeting		28/11/14	101.25KB	Share
CUV	Chairman's Address		28/11/14	87.82KB	Share
CUV	CEO's AGM presentation		28/11/14	4.08MB	Share
CUV	Letter to Shareholders		05/11/14	256.29KB	Share
CUV	Letter to Shareholders		03/11/14	299.92KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	29/10/14	150.11KB	Share
CUV	Clinuvel to host investor teleconference		28/10/14	83.46KB	Share
CUV	Annual Report to shareholders		27/10/14	1.18MB	Share
CUV	Notice of Annual General Meeting/Proxy Form		27/10/14	665.02KB	Share
CUV	SCENESSE attains breakthrough European Market Authorisation	PRICE SENSITIVE	27/10/14	131.83KB	Share
CUV	Trading Halt	PRICE SENSITIVE	24/10/14	240.88KB	Share
CUV	AGM Date		10/10/14	216.29KB	Share
CUV	Lapse and Forfeit of Unlisted Conditional Performance Rights		10/10/14	187.82KB	Share
CUV	SCENESSE data to be presented at EADV conference		08/10/14	92.14KB	Share
CUV	EMA Oral Explanation Update	PRICE SENSITIVE	26/09/14	90.07KB	Share
CUV	Clinuvel invited to present at EMA's CHMP plenary session		22/09/14	299.84KB	Share
CUV	Clinuvel enters a joint venture with Biotech Lab Singapore	PRICE SENSITIVE	19/09/14	281.14KB	Share
CUV	JAMA Dermatology publishes SCENESSE vitiligo study results	PRICE SENSITIVE	19/09/14	152KB	Share
CUV	Response to ASX Price Query	PRICE SENSITIVE	16/09/14	536.23KB	Share
CUV	Change in substantial holding		12/09/14	890.53KB	Share
CUV	Change in substantial holding		11/09/14	1.12MB	Share
CUV	Preliminary Final Report	PRICE SENSITIVE	25/08/14	2.05MB	Share
CUV	Chairman's Update		18/08/14	292.16KB	Share
CUV	Clinuvel declines unsolicited proposal from Retrophin	PRICE SENSITIVE	08/08/14	118.72KB	Share
CUV	Appendix 3B		07/08/14	549.84KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/14	33.46KB	Share
CUV	Final Director's Interest Notice		31/07/14	109.47KB	Share
CUV	Becoming a substantial holder		30/07/14	265.21KB	Share
CUV	Becoming a substantial holder		30/07/14	257.08KB	Share
CUV	Proposal to acquire all the outstanding shares in Clinuvel P		28/07/14	999.46KB	Share
CUV	Mr Jack Wood		28/07/14	85.15KB	Share
CUV	Clinuvel receives an unsolicited bid for the Company	PRICE SENSITIVE	28/07/14	89.73KB	Share
CUV	Clinuvel Newsletter July 2014		16/07/14	328.13KB	Share
CUV	US orphan-drug designation in Hailey-Hailey Disease	PRICE SENSITIVE	22/05/14	313.99KB	Share
CUV	s.708A Notice		20/05/14	34.01KB	Share
CUV	Becoming a substantial holder		20/05/14	52.63KB	Share
CUV	Appendix 3B		20/05/14	512.46KB	Share
CUV	Euro orphan designation in Hailey-Hailey Disease - SCENESSE		19/05/14	118.76KB	Share
CUV	Management Update	PRICE SENSITIVE	19/05/14	415.41KB	Share
CUV	Clinuvel placement	PRICE SENSITIVE	14/05/14	427.27KB	Share
CUV	Trading Halt Request		12/05/14	155.48KB	Share
CUV	Trading Halt	PRICE SENSITIVE	12/05/14	77.85KB	Share
CUV	Phase II vitiligo study commences in Singapore	PRICE SENSITIVE	06/05/14	368.83KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	17/04/14	150.32KB	Share
CUV	Lapse and Forfeit of Unlisted Conditional Performance Rights		14/04/14	189.38KB	Share
CUV	Clinuvel Newsletter April 2014		14/04/14	1.72MB	Share
CUV	SCENESSE data to feature at American Academy of Dermatology		20/03/14	129.81KB	Share
CUV	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/14	320.92KB	Share
CUV	Phase II study starts in skin disorder Hailey-Hailey Disease	PRICE SENSITIVE	10/02/14	301.25KB	Share
CUV	Clinuvel Newsletter		04/02/14	391.27KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/14	150.39KB	Share
CUV	EMA review of SCENESSE extended to mid-2014	PRICE SENSITIVE	30/01/14	355.3KB	Share
CUV	Letter to Shareholders		08/01/14	207.49KB	Share
CUV	Lapse and Forfeit of Unlisted Share Options		19/11/13	188.66KB	Share
CUV	Results of Meeting		12/11/13	98.38KB	Share
CUV	2013 AGM CEO's Presentation		12/11/13	5.31MB	Share

CUV Positive preliminary results in Singaporean vitiligo study
03/12/15	PRICE SENSITIVE	133.07KB	Share
CUV Results of Meeting
24/11/15		102KB	Share
CUV CEO's AGM Presentation
24/11/15		2.98MB	Share
CUV Chairman's Address to Shareholders
24/11/15		102.79KB	Share
CUV Change in substantial holding
04/11/15		3.33MB	Share
CUV Appendix 4C - quarterly
30/10/15	PRICE SENSITIVE	137.79KB	Share
CUV Appendix 4G and Corporate Governance Statement
23/10/15		679.3KB	Share
CUV Annual Report to shareholders
23/10/15		3.46MB	Share
CUV Notice of Annual General Meeting/Proxy Form
23/10/15		651.05KB	Share
CUV Change in substantial holding
07/10/15		559.76KB	Share
CUV AGM Date
06/10/15		254.13KB	Share
CUV FDA Meeting
05/10/15		268.27KB	Share
CUV Becoming a substantial holder
23/09/15		773.09KB	Share
CUV SCENESSE released for European Distribution
21/09/15	PRICE SENSITIVE	284.3KB	Share
CUV Preliminary Final Report
31/08/15	PRICE SENSITIVE	1.03MB	Share
CUV FDA grants Clinuvel a Type C Meeting
27/08/15	PRICE SENSITIVE	143.62KB	Share
CUV Appendix 4C - quarterly
31/07/15	PRICE SENSITIVE	138.06KB	Share
CUV Ceasing to be a substantial holder
30/07/15		159.82KB	Share
CUV Clinuvel Newsletter - July 2015
15/07/15		175.38KB	Share
CUV NEJM publishes Phase III SCENESSE studies
02/07/15	PRICE SENSITIVE	134.46KB	Share
CUV SCENESSE Commercialisation Update
05/06/15	PRICE SENSITIVE	282.58KB	Share
CUV Clinuvel announces innovative melanocortin
05/05/15	PRICE SENSITIVE	131.32KB	Share
CUV Appendix 4C - quarterly
27/04/15	PRICE SENSITIVE	137.52KB	Share
CUV Clinuvel Relocates Melbourne Office
31/03/15		205.87KB	Share
CUV Appendix 3B
20/03/15		547.71KB	Share
CUV SCENESSE data presented at US dermatology conference
20/03/15		119.32KB	Share
CUV SCENESSE breakthrough featured in peer-reviewed editorial
20/03/15		115.97KB	Share
CUV Clinuvel Newsletter - March 2015
12/03/15		1.09MB	Share
MPL +3PL AAC AAX ABY TSN ACO ACX AFA AFJ AGO AMI ANG APO ASH ASZ ATR AVG AWN AXZ AZZ BAL BCI BDR BGG BLA BLX BRL BYI CGW PRG COF AEL CPL CTD CTP CUV CVN CYG MCM DSH E88 EAX EHE EHL ELD K2P EML ENN FAR FML FPH TOY FWD GBG GBT GEG GFY ETM GMF GNE GNG GOR GOW GDA HCH HFR HGO HSN HUO HZN A1M ILU IMD IPD IPH IQE ISN IWG JIN LAU VBC LHC LOV LYC LYL FDM MDL MFG MGX MIG MIN MND MXI NAN NHF NTU NWF NWT WFL OCL OML PAN ATH PEN PGR PHI PME POS PSQ HYD REG RFF RHP RSG RUL SDA SDL SEK SFX SHJ SHV SIO SIQ SLX SOM SRF SYR TGA TIG TOF TRY TZN UBN VET VLW WLF WOR ZSP S&P DJ Indices Announces March Quarterly Review
06/03/15	PRICE SENSITIVE	100.19KB	Share
CUV Appendix 3B
02/03/15		550KB	Share
CUV Half Yearly Report and Accounts
25/02/15	PRICE SENSITIVE	265.55KB	Share
CUV Appendix 4C - quarterly
30/01/15	PRICE SENSITIVE	138.2KB	Share
CUV Change of Director's Interest Notice
23/01/15		728.77KB	Share
CUV Appendix 3B
23/01/15		549.52KB	Share
CUV Initial Director's Interest Notice
21/01/15		342.33KB	Share
CUV Clinuvel appoints new Non-Executive Director
21/01/15		210.85KB	Share
CUV European Commission approves SCENESSE
23/12/14	PRICE SENSITIVE	275.65KB	Share
CUV Change of Director's Interest Notice x 3
23/12/14		681.88KB	Share
CUV Appendix 3B
23/12/14		544.6KB	Share
CUV Long term use of SCENESSE in EPP published in BJD
15/12/14		121.02KB	Share
CUV Change in substantial holding
05/12/14		278.54KB	Share
CUV *Change of Director's Interest Notice 4**
04/12/14		857.15KB	Share
CUV Appendix 3B
04/12/14		548.6KB	Share
CUV Investor Update Presentation
04/12/14		1.13MB	Share
CUV Results of Meeting
28/11/14		101.25KB	Share
CUV Chairman's Address
28/11/14		87.82KB	Share
CUV CEO's AGM presentation
28/11/14		4.08MB	Share
CUV Letter to Shareholders
05/11/14		256.29KB	Share
CUV Letter to Shareholders
03/11/14		299.92KB	Share
CUV Appendix 4C - quarterly
29/10/14	PRICE SENSITIVE	150.11KB	Share
CUV Clinuvel to host investor teleconference
28/10/14		83.46KB	Share
CUV Annual Report to shareholders
27/10/14		1.18MB	Share
CUV Notice of Annual General Meeting/Proxy Form
27/10/14		665.02KB	Share
CUV SCENESSE attains breakthrough European Market Authorisation
27/10/14	PRICE SENSITIVE	131.83KB	Share
CUV Trading Halt
24/10/14	PRICE SENSITIVE	240.88KB	Share
CUV AGM Date
10/10/14		216.29KB	Share
CUV Lapse and Forfeit of Unlisted Conditional Performance Rights
10/10/14		187.82KB	Share
CUV SCENESSE data to be presented at EADV conference
08/10/14		92.14KB	Share
CUV EMA Oral Explanation Update
26/09/14	PRICE SENSITIVE	90.07KB	Share
CUV Clinuvel invited to present at EMA's CHMP plenary session
22/09/14		299.84KB	Share
CUV Clinuvel enters a joint venture with Biotech Lab Singapore
19/09/14	PRICE SENSITIVE	281.14KB	Share
CUV JAMA Dermatology publishes SCENESSE vitiligo study results
19/09/14	PRICE SENSITIVE	152KB	Share
CUV Response to ASX Price Query
16/09/14	PRICE SENSITIVE	536.23KB	Share
CUV Change in substantial holding
12/09/14		890.53KB	Share
CUV Change in substantial holding
11/09/14		1.12MB	Share
CUV Preliminary Final Report
25/08/14	PRICE SENSITIVE	2.05MB	Share
CUV Chairman's Update
18/08/14		292.16KB	Share
CUV Clinuvel declines unsolicited proposal from Retrophin
08/08/14	PRICE SENSITIVE	118.72KB	Share
CUV Appendix 3B
07/08/14		549.84KB	Share
CUV Appendix 4C - quarterly
31/07/14	PRICE SENSITIVE	33.46KB	Share
CUV Final Director's Interest Notice
31/07/14		109.47KB	Share
CUV Becoming a substantial holder
30/07/14		265.21KB	Share
CUV Becoming a substantial holder
30/07/14		257.08KB	Share
CUV Proposal to acquire all the outstanding shares in Clinuvel P
28/07/14		999.46KB	Share
CUV Mr Jack Wood
28/07/14		85.15KB	Share
CUV Clinuvel receives an unsolicited bid for the Company
28/07/14	PRICE SENSITIVE	89.73KB	Share
CUV Clinuvel Newsletter July 2014
16/07/14		328.13KB	Share
CUVUS orphan-drug designation in Hailey-Hailey Disease
22/05/14	PRICE SENSITIVE	313.99KB	Share
CUVs.708A Notice
20/05/14		34.01KB	Share
CUVBecoming a substantial holder
20/05/14		52.63KB	Share
CUVAppendix 3B
20/05/14		512.46KB	Share
CUVEuro orphan designation in Hailey-Hailey Disease - SCENESSE
19/05/14		118.76KB	Share
CUVManagement Update
19/05/14	PRICE SENSITIVE	415.41KB	Share
CUVClinuvel placement
14/05/14	PRICE SENSITIVE	427.27KB	Share
CUVTrading Halt Request
12/05/14		155.48KB	Share
CUVTrading Halt
12/05/14	PRICE SENSITIVE	77.85KB	Share
CUVPhase II vitiligo study commences in Singapore
06/05/14	PRICE SENSITIVE	368.83KB	Share
CUVAppendix 4C - quarterly
17/04/14	PRICE SENSITIVE	150.32KB	Share
CUVLapse and Forfeit of Unlisted Conditional Performance Rights
14/04/14		189.38KB	Share
CUVClinuvel Newsletter April 2014
14/04/14		1.72MB	Share
CUVSCENESSE data to feature at American Academy of Dermatology
20/03/14		129.81KB	Share
CUVHalf Yearly Report and Accounts
26/02/14	PRICE SENSITIVE	320.92KB	Share
CUVPhase II study starts in skin disorder Hailey-Hailey Disease
10/02/14	PRICE SENSITIVE	301.25KB	Share
CUVClinuvel Newsletter
04/02/14		391.27KB	Share
CUVAppendix 4C - quarterly
31/01/14	PRICE SENSITIVE	150.39KB	Share
CUVEMA review of SCENESSE extended to mid-2014
30/01/14	PRICE SENSITIVE	355.3KB	Share
CUVLetter to Shareholders
08/01/14		207.49KB	Share
CUVLapse and Forfeit of Unlisted Share Options
19/11/13		188.66KB	Share
CUVResults of Meeting
12/11/13		98.38KB	Share
CUV2013 AGM CEO's Presentation
12/11/13		5.31MB	Share

REFRESH

First 5 6 7 8 9

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $12.22		Change 0.020(0.16%)		Mkt cap ! $612.5M

Open	High	Low	Value	Volume
$12.14	$12.36	$12.10	$558.7K	45.71K

Buyers (Bids)

No.	Vol.	Price($)
1	50	$12.15

Sellers (Offers)

Price($)	Vol.	No.
$12.37	433	1

View Market Depth

No.	Vol.	Price($)
1	100	12.140
2	2282	12.050
4	1401	12.000
2	3674	11.970
3	924	11.900

Price($)	Vol.	No.
12.370	433	1
12.440	800	1
12.450	100	1
12.750	48	1
12.800	600	1

Last trade - 16.10pm 08/08/2025 (20 minute delay)

CUV (ASX) Chart

CLINUVEL PHARMACEUTICALS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories